-- Poster Board No. 915-II: Longer Duration of Thalidomide Monotherapy
Results in Improved Outcome in Relapsed/refractory Multiple Myeloma
-- Poster Board No. 905-II: A Phase I/II Trial on Melphalan, Prednisone,
Thalidomide, and Defribotide Combination in Relapsed/Refractory
Multiple Myeloma Patients (Abstract #2715).
-- Poster Board No. 908-II: Prolonged Progression Free Survival Does Not
Relate to Quality of Response to Treatment with Thalidomide in Patients
with Relapsed Multiple Myeloma (Abstract #2718).
-- Poster Board No. 919-II: ThaDD-V Treatment for Patients with
Relapsed/Refractory Multiple Myeloma: A Feasibility/Activity Study
-- Poster Board No. 924-II: Effect of Thrombotic Events on Overall
Survival in Patients with Newly Diagnosed Myeloma: Analysis from a
Randomized Phase III Trial of Thalidomide plus Dexamethasone vs
Dexamethasone in Newly Diagnosed Multiple Myeloma (E1A00) (Abstract
Date / Time / Location: December 10, 2007; Viewing 10:30 a.m.-7:00
p.m., Presentation 5:00-7:00 p.m., Hall B4 of Georgia World Congress Center
Session: Myeloma: Novel Therapies
-- Poster Board No 812-III: Thalidomide Combinations Improve Response
Rates; Results from the MRC IX Study (Abstract 3593).
About Thalidomide Pharmion
Thalidomide Pharmion is approved in Australia, New Zealand, Turkey,
Israel, South Korea and Thailand for the treatment of multiple myeloma
after the failure of standard therapies. In markets where Thalidomide
Pharmion is not approved, such as the E.U., Thalidomide is currently
provided by Pharmion on a named pati
|SOURCE Pharmion Corporation|
Copyright©2007 PR Newswire.
All rights reserved